Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Trodelvy/Keytruda patients had 11.2 months progression-free survival vs 7.8 months for chemotherapy/Keytruda ASCO says Trodelvy/Keytruda likely to become standard of care Patients still being ...